Similar articles

Abstract: During the development and progression of severe acute pancreatitis (SAP), conspicuous immune dysregulation develops, which is mainly manifested as excessive immune response in the early stage and immunosuppression in the late stage. This process involves complex changes in a variety of immune molecules and cells, such as cytokines, complements, lymphocytes, and leukocytes. With the gradual deepening of studies on the development and progression of SAP, the role of immune dysregulation in the pathogenesis of SAP has attracted more and more attention. In this article, we review the advances in research on the immune dysregulation in SAP and the immunotherapy of this disease through exploring the formation of excessive immune response and immune suppression as well as their mutual transformation.

[1] Al Mofleh, I.A., 2008. Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J. Gastroenterol., 14(5):675-684.

[2] Armutcu, F., Coskun, O., Gürel, A., Kanter, M., Can, M., Ucar, F., Unalacak, M., 2005. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin. Biochem., 38(6):540-547.

[3] Ayala, A., Chung, C.S., Song, G.Y., Chaudry, I.H., 2001. IL-10 mediation of activation-induced TH1 cell apoptosis and lymphoid dysfunction in polymicrobial sepsis. Cytokine, 14(1):37-48.

[4] Beger, H.G., Rau, B.M., 2007. Severe acute pancreatitis: clinical course and management. World J. Gastroenterol., 13(38):5043-5051.

[5] Chen, C., Xia, S.H., Chen, H., Li, X.H., 2008. Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. World J. Gastroenterol., 14(30):4735-4738.

[6] Chen, X.L., Huang, X.L., Wu, H., 2002. Modulation of disorder of inflammatory-associated cytokines with immuno-suppressive agents in acute pancreatitis. Chinese Journal of Bases and Clinics in General Surgery, 9(6):384-387 (in Chinese).

[7] DiMagno, M.J., DiMagno, E.P., 2007. New advances in acute pancreatitis. Curr. Opin. Gastroenterol., 23(5):494-501.

[8] Fink, M.P., 2008. Ethyl pyruvate. Curr. Opin. Anaesthesiol., 21(2):160-167.

[9] Frossard, J.L., Steer, M.L., Pastor, C.M., 2008. Acute pancreatitis. Lancet, 371(9607):143-152.

[10] Fushimi, T., Okayama, H., Seki, T., Shimura, S., Shirato, K., 1997. Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes. Int. Arch. Allergy Immunol., 112(1):13-18.

[11] Gloor, B., Stahel, P.F., Müller, C.A., Schmidt, O.I., Büchler, M.W., Uhl, W., 2003. Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis. Scand. J. Gastroenterol., 38(10):1078-1082.

[12] Han, X.C., Zhang, Y.C., Wang, Y., Jia, M.K., 2003. Clinical evaluation of serum interleukin 10 in patients with acute pancreatitis. Hepatobiliary Pancreat. Dis. Int., 2(1): 135-138.

[13] Hartwig, W., Klafs, M., Kirschfink, M., Hackert, T., Schneider, L., Gebhard, M.M., Büchler, M.W., Werner, J., 2006. Interaction of complement and leukocytes in severe acute pancreatitis: potential for therapeutic intervention. Am. J. Physiol. Gastrointest. Liver Physiol., 291(5):G844-G850.

[14] Hayashi, T., Ishida, Y., Kimura, A., Iwakura, Y., Mukaida, N., Kondo, T., 2007. IFN-gamma protects cerulein-induced acute pancreatitis by repressing NF-kappa B activation. J. Immunol., 178(11):7385-7394.

[15] Iwagaki, H., Hizuta, A., Uomoto, M., Takeuchi, Y., Kohoka, H., Okamoto, T., Tanaka, N., 1997. Clinical value of cytokine antagonists in infectious complications. Res. Commun. Mol. Pathol. Pharmacol., 96(1):25-34.

[16] Krivoruchko, I.A., Boĭko, V.V., Pesotskiĭ, O.N., Shevchenko, R.S., Klimova, E.M., Drozdova, L.A., 2003. The role of immune disorders information of local and systemic complications of severe acute pancreatitis. Klin. Khir., (2):20-24 (in Russian).

[17] Kylänpää-Bäck, M.L., Takala, A., Kemppainen, E., Puolakkainen, P., Kautiainen, H., Jansson, S.E., Haapiainen, R., Repo, H., 2001. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scand. J. Gastroenterol., 36(10):1100-1107.

[18] Kylanpaa, M.L., Mentula, P., Kemppainen, E., Puolakkainen, P., Aittomaki, S., Silvennoinen, O., Haapiainen, R., Repo, H., 2005. Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-gamma in vitro. Pancreas, 31(1):23-27.

[19] Ma, M., Geng, Z.Q., He, X.Y., 2002. Improving the prognosis of severe acute pancreatitis by using dexamethasone inhibiting inflammatory mediators. Journal of the Fourth Military Medical University, 23(10):932-934 (in Chinese).

[20] Ma, T., Kang, C., Shao, H., Qi, Q., Hu, W., 2006. Protective effects of ulinastatin on proliferation and cytokine release of splenocytes from rats with severe acute pancreatitis. Eur. Surg. Res., 38(5):445-450.

[21] Malleo, G., Mazzon, E., Siriwardena, A.K., Cuzzocrea, S., 2007. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock, 28(2):130-140.

[22] Matsumura, N., Takeyama, Y., Ueda, T., Yasuda, T., Shinzeki, M., Sawa, H., Nakajima, T., Kuroda, Y., 2007. Decreased expression of toll-like receptor 2 and 4 on macrophages in experimental severe acute pancreatitis. Kobe. J. Med. Sci., 53(5):219-227.

[23] Ohmoto, K., Yamamoto, S., 2005. Serum interleukin-6 and interleukin-10 in patients with acute pancreatitis: clinical implications. Hepatogastroenterology, 52(64):990-994.

[24] Paulino, E.C., de Souza, L.J., Molan, N.A., Machado, M.C., Jancar, S., 2007. Neutrophils from acute pancreatitis patients cause more severe in vitro endothelial damage compared with neutrophils from healthy donors and are differently regulated by endothelins. Pancreas, 35(1): 37-41.

[25] Pietruczuk, M., Dabrowska, M.I., Wereszczynska-Siemiatkowska, U., Dabrowski, A., 2006. Alteration of peripheral blood lymphocyte subsets in acute pancreatitis. World J. Gastroenterol., 12(33):5344-5351.

[26] Pooran, N., Indaram, A., Singh, P., Bank, S., 2003. Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis. J. Clin. Gastroenterol., 37(3):263-266.

[27] Rau, B.M., Krüger, C.M., Hasel, C., Oliveira, V., Rubie, C., Beger, H.G., Schilling, M.K., 2006. Effects of immunosuppressive and immunostimulative treatment on pancreatic injury and mortality in severe acute experimental pancreatitis. Pancreas, 33(2):174-183.

[28] Romagnani, S., 2000. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol., 85(1):9-18.

[29] Roxvall, L., Bengtson, A., Sennerby, L., Heideman, M., 1991. Activation of the complement cascade by trypsin. Biol. Chem. Hoppe. Seyler., 372(4):273-278.

[30] Schütte, K., Malfertheiner, P., 2008. Markers for predicting severity and progression of acute pancreatitis. Best Pract. Res. Clin. Gastroenterol., 22(1):75-90.

[31] Sjogren, M.H., 2004. Thymalfasin: an immune system enhancer for the treatment of liver disease. J. Gastroenterol. Hepatol., 19(s6):S69-S72.

[32] Skipworth, J.R., Pereira, S.P., 2008. Acute pancreatitis. Curr. Opin. Crit. Care, 14(2):172-178.

[33] Ueda, T., Takeyama, Y., Yasuda, T., Shinzeki, M., Sawa, H., Nakajima, T., Ajiki, T., Fujino, Y., Suzuki, Y., Kuroda, Y., 2006. Immunosuppression in patients with severe acute pancreatitis. J. Gastroenterol., 41(8):779-784.

[34] Yao, W., Zhu, Q., Yuan, Y., Qiao, M., Zhang, Y., Zhai, Z., 2007. Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level. J. Gastroenterol. Hepatol., 22(11):1866-1871.

[35] Yasuda, T., Takeyama, Y., Ueda, T., Takase, K., Nishikawa, J., Kuroda, Y., 2002. Splenic atrophy in experimental severe acute pancreatitis. Pancreas, 24(4):365-372.